Hip Fracture News and Research

RSS

IOF urges clinicians in Asia to prepare for escalating crisis of osteoporosis among elderly people

The International Osteoporosis Foundation is calling on doctors in the Asia-Pacific region to prepare for an immense rise in the number of elderly people suffering broken bones as a result of osteoporosis.

20 Jun 2016

Study examines effectiveness of high-load resistance training in improving older men’s bone strength

Big improvements in bone and muscle strength with no injuries is expected to be the outcome of a Griffith University study training men aged over 50 with low bone mass.

17 Jun 2016

$More than 7 in 10 older hip fracture patients not aware of having osteoporosis$

More than 7 in 10 older hip fracture patients not aware of having osteoporosis

More than 7 in 10 older adults who suffer hip fractures aren't told they have the bone-weakening disease osteoporosis - despite the fact that hip fractures nearly always signify the presence of this potentially debilitating condition, according to revealing new research by Northwell Health physicians.

19 May 2016

UK-wide study reveals AOD prescription rates for women decrease in last 10 years

A UK-wide study looking at the prescribing of anti-osteoporotic drugs (AOD) to people aged 50 years or above has found that, since 2006, AOD prescription rates for women have decreased and rates for men have levelled off, despite a growing elderly population and associated fracture risks.

19 May 2016

Study highlights importance of routine osteoporosis screening for men

Screening women for osteoporosis is now routine, however, when it comes to men, most are never screened and therefore suffer the consequences of the disease. In the U.S., nearly 1.5 million men over 65 have osteoporosis, and another 3.5 million men are at risk for developing the disease.

6 May 2016

High coronary artery calcium score puts people at greater risk for cancer, kidney disease and COPD

A 10-year follow-up study of more than 6,000 people who underwent heart CT scans suggests that a high coronary artery calcium score puts people at greater risk not only for heart and vascular disease but also for cancer, chronic kidney disease and chronic obstructive pulmonary disease (COPD).

10 Mar 2016

Hypothermia associated with increased risk for infection in patients undergoing surgery

A Henry Ford Hospital finds that hypothermia, a relatively common but unintentional occurrence during surgery, is associated with an increased risk for infection in patients who undergo surgery to repair a hip fracture.

3 Mar 2016

Report: One in two Americans affected by musculoskeletal condition

An estimated 126.6 million Americans (one in two adults) are affected by a musculoskeletal condition--comparable to the total percentage of Americans living with a chronic lung or heart condition--costing an estimated $213 billion in annual treatment, care and lost wages, according to a new report issued today by the United States Bone and Joint Initiative.

2 Mar 2016

$Falls, fractures may precede Parkinson’s disease by decades$

Falls, fractures may precede Parkinson’s disease by decades

People who later develop Parkinson’s disease have an increased tendency to fall and injure themselves, being at particular risk of hip fracture, a study shows.

5 Feb 2016

$Major bone fracture may increase risk of widespread chronic body pain in later life$

Major bone fracture may increase risk of widespread chronic body pain in later life

Breaking a major bone may increase risk of widespread chronic body pain in later life, a new study has found.

6 Jan 2016

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

17 Nov 2015

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

A drug approved to treat rheumatoid arthritis, tocilizumab (Actemra, Genentech), is a potential new therapy for patients with polymyalgia rheumatica, according to an open-label, phase II study presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on November 10.

11 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015

Vertical jump could predict lower body bone strength in adolescents

Every year at least 250,000 older Americans are hospitalized for hip fractures. It is hard to recover from a hip fracture, and many people lose their independence afterward. Low bone strength during the growing the years can lead to a greater chance of having a hip fracture as an older adult.

30 Oct 2015

Low-weight, high-repetition resistance training increases bone density in adults

A new research study published in The Journal of Sports Medicine and Physical Fitness finds that low-weight, high-repetition resistance training increases bone mineral density in adults, challenging assumptions that heavy weight-training is required to build bone mineral density. Participants who completed the study experienced up to 8 percent bone mineral density increases in the legs, pelvis, arms and spine.

27 Oct 2015

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.

20 Oct 2015

Lack of patient understanding of the true cost of medication non-adherence

A new report released today, Friday 16th October, by Omnicell, throws the spotlight on the ‘missing millions’ in the NHS and the staggering cost to the nation of medication non-adherence.

16 Oct 2015

$Study suggests that high-volume nursing facilities better for hip fracture patients$

Study suggests that high-volume nursing facilities better for hip fracture patients

There isn't a lot of information available to help family caregivers choose the best skilled nursing facility for an elderly loved one who breaks a hip, but a new study suggests a potentially useful quality indicator: the facility's number of hip fracture patients during the prior year.

30 Sep 2015

$Bisphosphonate drugs linked to greater risk of atypical hip fractures$

Bisphosphonate drugs linked to greater risk of atypical hip fractures

The use of bisphosphonates, a group of drugs used to prevent hip breakages in women with osteoporosis, is associated with an increased risk of atypical fractures in this joint, understood as those that occur in less frequent locations.

22 Sep 2015

$Common Alzheimer's disease drug increases bone density, reduces fracture risks$

Common Alzheimer's disease drug increases bone density, reduces fracture risks

The most common drug used to treat Alzheimer's disease increases bone mass in mice, according to one of the first research articles published in the new open access journal Heliyon. The authors of the study, from Saitama Medical University in Japan, say this means the drug could also be used to treat bone loss diseases like osteoporosis and periodontitis, following further clinical research.

21 Sep 2015